Summary of CRS and neurologic events Summary of CRS and neurologic events
  • In ZUMA-3, 96% of CRS events (n=69/72) and 91% of neurologic events (n=48/53) resolved2

Most symptoms of CRS and neurologic events occurred early
and were generally manageable
using established guidance1,3


Guidance for monitoring and management of CAR T-related adverse reactions (CRS and neurologic events)1

See full Prescribing Information See full Prescribing Information
Ensure that 2 doses of tocilizumab are available for each patient prior to infusion. For more information on CRS and neurologic events management, please see the full Prescribing Information for TECARTUS®
Monitor patients for signs and symptoms of adverse reactions for 4 weeks postinfusion Monitor patients for signs and symptoms of adverse reactions for 4 weeks postinfusion
Continue to monitor patients for signs or symptoms of these adverse reactions for 4 weeks postinfusion
TECARTUS® Authorized Treatment Center TECARTUS® Authorized Treatment Center
Monitor patients daily for at least 14 days postinfusion at the Authorized Treatment Center for signs and symptoms of CRS and neurologic events
Seek immediate medical attention for signs or symptoms of CRS or neurologic events Seek immediate medical attention for signs or symptoms of CRS or neurologic events
Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic events occur at any time

In the ZUMA-3 trial4

  • Patients with Grade >1 treatment-related CRS or neurologic events remained hospitalized until the adverse reaction resolved
  • Discharge occurred only after all treatment-related nonhematologic toxicities returned to Grade ≤1 or baseline

AEs=adverse events; ALL=acute lymphoblastic leukemia; CAR T=chimeric antigen receptor T cell; CRS=cytokine release syndrome; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file. Kite Pharma, Inc; 2021. 3. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 4. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study – supplementary appendix. Lancet. Published online June 4, 2021. doi:10.1016/S0140-6736(21)01222-8